Share this video  

ASCO GI 2021 | Durvalumab and PET-directed CRT after induction FOLFOX for esophageal adenocarcinoma.

Geoffrey Ku, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the results of a study evaluating durvalumab, an anti-PD-L1 antibody, and PET-directed chemoradiation (CRT) after induction FOLFOX for patients with esophageal adenocarcinoma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).


Dr Ku reports Apexigen (consulting), AstraZeneca (research support), BMS (research support, consulting), Daiichi-Sankyo (research support), Merck (research support, consulting), Oncolys (research support), Pieris (research support, consulting), Zymeworks (research support).